MEet our dedicated team of scientists and researchers
Pedro Correa de Sampaio, PH.D.
Co-founder and CEO
Tumour microenvironment expert with over 12 years of research experience in top institutions including CRUK Cambridge Institute and MD Anderson Cancer Center. Authored multiple publications in immunooncology and contributed to development of innovative IO cell therapies at Triumvira Immunologics.
Annelise Soulier, Ph.D.
Co-founder and CSO
Expert in molecular biology, microbiology and bacterial engineering. Formerly at Prokarium, with over 7 years experience in the engineering and development of bacterial therapeutic products for different disease indications. Co-inventor of patented engineered live biotherapeutics currently in clinical trials.
Keith Blundy, Ph.D.
Director and Chairperson
Former Chief Executive Officer of Cancer Research Technology and STORM Therapeutics, with experience in strategy & licensing, drug development and venture capital fund raising. Formerly a director of KuDOS Pharmaceuticals Ltd, Mission Therapeutics, and Inivata Ltd.
Laura Fletcher, PH.D.
Investor Director (Deep Science Ventures)
Business development professional with proven success in oncology commercial deals (including licences, alliances, and spin outs). Formerly at Cancer Research UK, responsible for leading outlicensing deals with Pharma partners such as AstraZeneca, Janssen Biotech and Ono Pharma.
JULIE WOLF, Ph.D.
Investor Director (2048 Ventures)
Leads biotech and healthcare verticals at 2048 Ventures, with an impressive track record of investments in over 50 startups. Was previously Chief Scientific Officer and a member of the founding investment team at SOSV’s IndieBio New York.
IMELDA JUNIARSIH, PHD
Investor Director (Pioneer Group)
Dr. Imelda Juniarsih is an Investment Associate Director at Pioneer Group specializing in life sciences, biotech, and MedTech. Recognized as a Top 50 Mover and Shaker in BioBusiness (2018), she advises early-stage healthcare startups on IP, commercialization, and investment strategy. She holds a PhD in Biotechnology from the University of Manchester.
Torquil Jackson, Ph.D.
Board Observer (Cancer Research Horzions)
Torquil is Investment Manager for Cancer Research Horizons' Ventures team. He identifies and evaluates high-impact oncology investments and supports entrepreneurial Cancer Research UK investigators in developing potential start-ups to accelerate their scientific breakthroughs. Prior to Cancer Research Horizons, Torquil completed his BSc in pharmacology, PhD in the neurobiology of Duchenne muscular dystrophy in the brain, and has published five papers.
JULES ROGNON
Founder’s Associate
JOE TURNER
Fractional CFO
Sandie mcCULLOCH
Executive Assistant
Sheila JOHNSON
Fractional People and Culture Professional
Abigail LITTLE, PHD
Senior Scientist
UDO WEGMANN, PhD
Principal Scientist
ZEE YAU (JOELLE) SENG
Lab Placement Student
Varun lawrence
Senior Scientist
Clinical Advisors
RAMY IBRAHIm
Immunooncology
Tony awad
CMC and Regulatory
LONE OTTESEN
Clinical Oncology
DEBRA BARKER
LBPs and Oncology
Research backed by leading scientific partners
Real therapeutic breakthroughs come when likeminded innovators work together to drive patient benefits. Our collaborative programmes with leading academics in synbio and immunology are integral to the core of our technology. We are backed by visionary investors who support us in our vision to enable therapeutic efficacy through next generation engineered live biotherapeutics.